Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Rev. bras. cir. cardiovasc ; 32(2): 96-103, Mar.-Apr. 2017. tab
Artículo en Inglés | LILACS | ID: biblio-843481

RESUMEN

Abstract INTRODUCTION: The mortality due to cardiogenic shock complicating acute myocardial infarction (AMI) is high even in patients with early revascularization. Infusion of low dose recombinant human brain natriuretic peptide (rhBNP) at the time of AMI is well tolerated and could improve cardiac function. OBJECTIVE: The objective of this study was to evaluate the hemodynamic effects of rhBNP in AMI patients revascularized by emergency percutaneous coronary intervention (PCI) who developed cardiogenic shock. METHODS: A total of 48 patients with acute ST segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock and whose hemodynamic status was improved following emergency PCI were enrolled. Patients were randomly assigned to rhBNP (n=25) and control (n=23) groups. In addition to standard therapy, study group individuals received rhBNP by continuous infusion at 0.005 µg kg−1 min−1 for 72 hours. RESULTS: Baseline characteristics, medications, and peak of cardiac troponin I (cTnI) were similar between both groups. rhBNP treatment resulted in consistently improved pulmonary capillary wedge pressure (PCWP) compared to the control group. Respectively, 7 and 9 patients died in experimental and control groups. No drug-related serious adverse events occurred in either group. CONCLUSION: When added to standard care in stable patients with cardiogenic shock complicating anterior STEMI, low dose rhBNP improves PCWP and is well tolerated.


Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Péptido Natriurético Encefálico/administración & dosificación , Infarto de la Pared Anterior del Miocardio/tratamiento farmacológico , Intervención Coronaria Percutánea/mortalidad , Infarto del Miocardio con Elevación del ST/tratamiento farmacológico , Choque Cardiogénico/etiología , Presión Sanguínea/efectos de los fármacos , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/farmacología , Presión Esfenoidal Pulmonar/efectos de los fármacos , Análisis de Varianza , Péptido Natriurético Encefálico/uso terapéutico , Péptido Natriurético Encefálico/farmacología , Infarto de la Pared Anterior del Miocardio/complicaciones , Infarto de la Pared Anterior del Miocardio/mortalidad , Infarto del Miocardio con Elevación del ST/complicaciones , Infarto del Miocardio con Elevación del ST/mortalidad , Frecuencia Cardíaca/efectos de los fármacos , Contrapulsador Intraaórtico/métodos
2.
Rev. chil. obes ; 6(1): 5-15, 2001. tab
Artículo en Español | LILACS | ID: lil-314845

RESUMEN

In the last decade, specially after the discovery of leptin, several neuropeptides that regulate energy intake and expenditure have been described in animal models. This has partially unvelied the underlying mechanisms that regulate body composition and weight and therefore a promise of a more effective treatment of obesity and its comorbidities is ad portas


Asunto(s)
Humanos , Diabetes Mellitus Tipo 2 , Resistencia a la Insulina , Obesidad , Regulación del Apetito/genética , Ácidos Grasos/genética , Acilación , Diabetes Mellitus Tipo 2 , Dopamina , Factor Natriurético Atrial/farmacología , Hipertensión/etiología , Leptina , Lipólisis , Biología Molecular , Mutación/genética , Neuropéptidos/farmacología , Obesidad , Péptido Natriurético Encefálico/farmacología , Péptido Natriurético Tipo-C/farmacología , Proliferadores de Peroxisomas , Proteínas Tirosina Fosfatasas/farmacología , Receptores Adrenérgicos beta/genética , Desacopladores
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA